Size-exclusion chromatography purification of high-titer vesicular stomatitis virus G glycoprotein-pseudotyped retrovectors for cell and gene therapy applications

Human Gene Therapy

Volumn 14, Issue 12, 2003, Pages 1139-1153

  Transfiguracion, Julia ^a   Jaalouk, Diana E ^b   Ghani, Karim ^a   Galipeau, Jacques ^b   Kamen, Amine ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE SERUM ALBUMIN; DEOXYRIBONUCLEASE; GENOMIC DNA; GREEN FLUORESCENT PROTEIN; PLASMID DNA; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS G GLYCOPROTEIN; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

ARTICLE; BONE MARROW CELL; CELLULAR DISTRIBUTION; ELECTRON MICROSCOPY; FLOW CYTOMETRY; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; NONHUMAN; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; REPRODUCIBILITY; STROMA CELL; ULTRACENTRIFUGATION; VESICULAR STOMATITIS VIRUS; VIRAL GENE THERAPY; VIRUS ENVELOPE; VIRUS PARTICLE; VIRUS PURIFICATION;

BOVINAE; RNA VIRUSES; UNIDENTIFIED RETROVIRUS; VESICULAR STOMATITIS VIRUS;

EID: 0043269712     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303403322167984     Document Type: Article

References (39)

1. ABOUD, M., WOLFSON M., HASSAN, Y., and HULEIHEL, M. (1982). Rapid purification of extracellular and intracellular Moloney murine leukemia virus. Arch. Virol. 71, 185-195.
2. ALAIN, R. (1997). Quantitation of virus particles by negative stain electron microscopy. Microsc. Today 97, 20.
3. ALAIN, R., NADON, F., SEGUIN, C., PAYMENT, P., and TRUDEL, M. (1987). Rapid virus subunit visualization by direct sedimentation of samples on electron microscope grids. J. Virol. Methods 16, 209-216.
4. ANDREADIS, S.T., BROTT, D., FULLER, A.O., and PALSSON, B.O. (1997). Moloney murine leukemia virus-derived retroviral vectors decay intracellularly with a half life in the range of 5.5 to 7.5 hours. J. Virol. 71, 7541-7548.
5. ANDREADIS, S.T., ROTH, C.M., LE DOUX, J.M., MORGAN, J.R., and YARMUSH, M.L. (1999). Large-scale processing of recombinant retroviruses for gene therapy. Biotechnol. Prog. 15, 1-11.
6. ANDREADIS, S., LAVERY, T., DAVIS, E.H., LE DOUX, J.M., YARMUSH, M.L., and MORGAN, J.R. (2000). Toward a more accurate quantitation of the activity of recombinant retroviruses: Alternatives to titer and multiplicity of infection. J. Virol. 74, 3431-3439.
7. BAJAJ, B., LEI, P., and ANDREADIS, S.T. (2001). High efficiencies of gene transfer with immobilized recombinant retrovirus: Kinetics and optimization. Biotechnol. Prog. 17, 587-596.
8. BIEGANSKI, R.M., FOWLER, A., MORGAN, J.R., and TONER, M. (1998). Stabilization of active recombinant retroviruses in an amorphous dry state with trehalose. Biotechnol. Prog. 14, 615-620.
9. BOWLES, N.E., EISENSMITH, R.C., MOHUIDDIN, R., PYRON, M., and WOO, S.L. (1996). A simple and efficient method for the concentration and purification of recombinant retrovirus for increased hepatocyte transduction in vivo. Hum. Gene Ther. 7, 1735-1742.
10. BRAAS, G., SEARLE, P.F., SLATER, N.K., and LYDDIATT, A. (1996). Strategies for the isolation and purification of retroviral vectors for gene therapy. Bioseparation 6, 211-228.
11. BURNS, J.C., FRIEDMANN, T., DRIEVER, W., BURRASCANO, M., and YEE, J.K. (1993). Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and non-mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 90, 8033-8037.
12. CHEN, J., REEVES, L., SANBURN, N., CROOP, J., WILLIAMS, D.A., and CORNETTA, K. (2001). Packaging cell line DNA contamination of vector supernatants: Implication for laboratory and clinical research. Virology 30, 186-197.
13. CHESEBRO, B., BRITT, W., EVANS, L., WEHRLY, K., NISHIO, J., and CLOYD, M. (1983). Characterization of monoclonal antibodies reactive with murine leukemia viruses: Use in analysis of strains of friend MCF and Friend ecotropic murine leukemia virus. Virology 127, 134-148.
14. FORESTELL, S.P., BOHNLEIN, E., and RIGG, R.J. (1995). Retroviral end-point titer is not predictive of gene transfer efficiency: Implications for vector production. Gene Ther. 2, 723-730.
15. GALIPEAU, J., LI, H., PAQUIN, A., SICILIA, F., KARPATI, G., and NALBANTOGLOU, J. (1999). Vesicular stomatitis virus G pseudotyped retrovector mediates effective in vivo suicide gene delivery in experimental brain cancer. Cancer Res. 15, 2384-2394.
16. GERSON, S.L. (1999). Mesenchymal stem cells: No longer second class marrow citizens. Nat. Med. 5, 262-264.
17. HAGEL, L., ÖSTBERA, M, and ANDERSON, T. (1996). Apparent pore size distributions of chromatography media. J. Chromatogr. A 743, 33-42.
18. HIGASHIKAWA, F., and CHANG, L. (2001). Kinetic analyses of stability of simple and complex retroviral vectors. Virology 280, 124-131.
19. JAALOUK, D.E., ELIOPOULOUS, N., COUTURE, C., MADER, S., and GALIPEAU, J. (2000). Glucocorticoid-inducible retrovector for regulated transgene expression in genetically engineered bone marrow stromal cells. Hum. Gene Ther. 11, 1837-1849.
20. KOTANI, H., NEWTON, P.B.I., ZHANG, S., CHIANG, Y.L., OTTO, E., WEAVER, L., BALESE, R.M., ANDERSON, W.F., and MC-GARRITY, G.J. (1994). Improved method for retroviral vector transduction and production for gene therapy. Hum. Gene Ther. 5, 19-28.
21. KUIPER, M., SANCHES, R.M., WALFORD, J.A., and SLATER, N.K.H. (2002). Purification of a functional gene therapy vector derived from Moloney murine leukemia virus using membrane filtration and ceramic hydroxyapatite chromatography. Biotechnol. Bioeng. 80, 445-453.
22. LE DOUX, J.M., MORGAN, J.R., SNOW, R.G., and YARMUSH, M.L. (1996). Proteoglycans secreted by packaging cell lines inhibit retrovirus infection. J. Virol. 70, 6468-6473.
23. LE DOUX, J.M., MORGAN, J.R., and YARMUSH, M.L. (1998). Removal of proteoglycans increases efficiency of retroviral gene transfer. Biotechnol. Bioeng. 58, 23-34.
24. LE DOUX, J.M., MORGAN, J.R., and YARMUSH, M.L. (1999). Differential inhibition of retrovirus transduction by proteoglycans and free glycosaminoglycans. Biotechnol. Prog. 15, 397-406.
25. LIU, M.L., KALAIZIC, I., STOVER, M.IL., ROWE, D.W., and LICHTER, A.C. (2001). Human bone marrow stromal cells are efficiently transduced by vesicular stomatitis virus-pseudotyped retrovecors without affecting subsequent osteoblastic differentiation. Bone 29, 331-335.
26. MAKINO, M., ISHIKAWA, G., YAMAGUCHI, K., OKADA, Y., WATANABE, K., SASAKI-IWAKI, Y., MANABE, S., HONDA, M., and KOMURO, K. (1994). Concentration of live retrovirus with a regenerated cellulose hollow fiber, BMM. Arch. Virol. 139, 87-96.
27. MCGRATH, M., WITTE, O., PINCUS, T., and WEISMANN, I.L. (1978). Retrovirus purification: Method that conserves envelope glycoprotein and maximizes infectivity. J. Virol. 25, 923-927.
28. MORGAN, J.R., LE DOUX, J.M., SNOW, R.G., TOMPKINS, R.G., and YARMUSH, M.L. (1995). Retrovirus infection: Effect of time and target cell number. J. Virol. 69, 6994-7000.
29. MORGENSTERN, J.P., and LAND, H. (1990). Advanced mammalian gene transfer: High titer retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18, 3587-3596.
30. ORY, D.S., NEUGEBOREN, B.A., and MULLIGAN, R.C. (1996). A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. U.S.A. 93, 11400-11406.
31. PAQUIN, A., JAALOUK, D.E., and GALIPEAU, J. (2001). Retrovector encoding a green fluorescent protein-herpes simplex virus thymidine kinase fusion protein serves as a versatile suicide/reporter for cell and gene therapy applications. Hum. Gene Ther. 12, 13-23.
32. PAUL, R.W., MORRIS, D., HESS, B.W., DUNN, J., and OVERELL, R.W. (1993). Increased viral titer through concentration of viral harvests from retroviral packaging lines. Hum. Gene Ther. 4, 609-615.
33. PHAM, L., YE, H., COSSET, F.L., RUSSELL, S.J., and PENG, K.W. (2001). Concentration of viral vectors by co-precipitation with calcium phosphate. J. Gene Med. 3, 188-194.
34. SCHERR, M., BATTMER, K., EDER, M., SCHULE, S., HOHENBERG, H., GANSER, A., GREZ, M., and BLOMER, U. (2002). Efficient gene transfer into CNS by lentiviral vectors purified by anion exchange chromatography. Gene Ther. 9, 1708-1714.
35. SCHIDLOVSKY, S. (1977). Structure of RNA tumor viruses. In: Recent Advances in Cancer Research: Cell Biology, Molecular Biology, and Tumor Virology. R.C. Gallo, ed. (CRC Press, Boca Raton, FL) pp. 189-245.
36. SLEPUSHKIN, V.A., COHEN, R., OGUNJIMI, K., JIANG, B., CHANG, N., DEAUSEN, E., HUMEAU, L., LI, Y., CONDE, B., LU, X., and DROPULIC, B. (2001). Development of a production process for clinical grade HIV-1 based lentiviral vector. Mol. Ther. 5, S308.
37. SOTTONG, P., HILL, P., FEENEY, M., KLECKER, J., JOHNSON, K., HARRIS, R., BELL, C., and STAFFORD, K. (1975). Recovery of murine leukemia virus from large volumes of freshly harvested culture fluids by using a single density gradient. Appl. Microbiol. 29, 102-105.
38. XU, L., YEE, J.K., WOLFF, J.A., and FRIEDMANN, T. (1989). Factors affecting long-term stability of Moloney murine leukemia virus-based vectors. Virology 171, 331-341.
39. YAMADA, K., MCCARTY, M., MADDEN, V.J., and WALSH, C.E. (2001). Purification of recombinant lentiviral vector by anion exchange chromatography. Mol. Ther. 5, S290.